Prostate Cancer

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

The Food and Drug Administration approved oral Nubeqa plus the chemotherapy docetaxel for patients with metastatic hormone-sensitive prostate cancer.

Treatment with primary radiotherapy was linked to an increased risk for the development of secondary primary cancers among a large group of men with localized prostate cancer, according to recent study findings.

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).

Drs Matthew Rettig and Jeremie Calais explain what it means to be a part of a collaborative team and how communication plays a big role in patients receiving optimal treatment.

Cancer treatment-related osteoporosis caused me to shrink two inches.

TAVT-45, an easy-to-swallow drug that can be suspended in water or juice, is being studied for the treatment of patients with metastatic prostate cancer.

Joseph Wood details his treatment journey with metastatic castration-resistant prostate cancer (mCRPC) and how the journey has impacted his wife and caregiver, Deborah Wood.

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

As I reflect on cancer survivorship, I notice how important the camraderie with fellow survivors is.

Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy.

Dr Matthew Rettig reviews the front-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and what factors are considered when choosing appropriate treatment.

While my wife has been an amazing caregiver throughout my cancer experience, I realized that it was not fair for her to continually be on the receiving end of all my negative emotions.

Joseph Wood, a patient, and Deborah Wood, Joseph’s wife and caregiver, talk about Joseph’s prostate cancer diagnosis and Deborah explains her role as a caregiver.

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should know before, during and after the scan.

Here is a roundup of cancer treatments that were approved by the FDA in the spring of 2022 that patients may have missed.

Looking back, perhaps a poem could have helped me tell my family about my cancer diagnosis.

Watch Dr. Jeremie Calais, Dr. Tian Zhang, Dr. Landon C. Brown and Jim Rosenfield answer questions about novel agents and strategies during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Landon C. Brown, from Atrium Health Levine Cancer Institute, discuss approaches to hormone therapy, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.